28 April 2021
: Case report 
Glycemic Profile of Intravenous Dexamethasone-Induced Hyperglycemia Using Continuous Glucose Monitoring
Unusual clinical course, Unusual or unexpected effect of treatment, Educational Purpose (only if useful for a systematic review or synthesis)
Fan Zhang12ABCDEF*, Jocelyne G. Karam13ABCDEFDOI: 10.12659/AJCR.930733
Am J Case Rep 2021; 22:e930733
Table 1. Timeline of the insulin dose adjustment and HA1C level.
| Date | HA1C | Diabetes regimens |
|---|---|---|
| Baseline | 7.3 | Detemir 50 units in AM and 50 units in PM, Metformin 1000 mg twice daily, Repaglinide 2 mg before meals, Pioglitazone 15 mg daily |
| Cancer diagnosed | 7.4 | Detemir 50 units in AM and 30 units in PM without hypoglycemia episodes. Prandial insulin lispro 5 units was added. Metformin and Repaglinide were discontinued at the beginning of chemotherapy |
| 3 months after cancer diagnosis | 7.5 | Detemir 50 units in AM and 30 units in PM. Prandial lispro insulin was increased to 15 units with correction lispro ISF 1: 25. CGM was started |
| 6 months after cancer diagnosis | 8.7 | Detemir 50 units in AM and 40 units in PM with correction lispro ISF 1: 18 on the first and second days following chemotherapy |
| 10 months after cancer diagnosis | 8.5 | Detemir 50 units in AM and 45 units in PM on the chemotherapy day and 40 units on the following night. ISF 1: 18 on both days |
| ISF – insulin sensitivity factor; CGM – continuous glucose monitoring. | ||